As mentioned earlier, the expression levels of both TFE3 and TP53 were upregulated in CRSwNP, thus the drugs that could make the biomarkers downregulated were selected as potential therapeutic agents for CRSwNP. The gene discussed is TFE3; the disease is chronic rhinosinusitis with nasal polyps.